BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 32651233)

  • 1. From overnutrition to liver injury: AMP-activated protein kinase in nonalcoholic fatty liver diseases.
    Zhao P; Saltiel AR
    J Biol Chem; 2020 Aug; 295(34):12279-12289. PubMed ID: 32651233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition.
    Huang H; Lee SH; Sousa-Lima I; Kim SS; Hwang WM; Dagon Y; Yang WM; Cho S; Kang MC; Seo JA; Shibata M; Cho H; Belew GD; Bhin J; Desai BN; Ryu MJ; Shong M; Li P; Meng H; Chung BH; Hwang D; Kim MS; Park KS; Macedo MP; White M; Jones J; Kim YB
    J Clin Invest; 2018 Dec; 128(12):5335-5350. PubMed ID: 30226474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cordycepin Ameliorates Nonalcoholic Steatohepatitis by Activation of the AMP-Activated Protein Kinase Signaling Pathway.
    Lan T; Yu Y; Zhang J; Li H; Weng Q; Jiang S; Tian S; Xu T; Hu S; Yang G; Zhang Y; Wang W; Wang L; Zhu Q; Rong X; Guo J
    Hepatology; 2021 Aug; 74(2):686-703. PubMed ID: 33576035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
    Farrell GC; Haczeyni F; Chitturi S
    Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis.
    Zhao P; Sun X; Chaggan C; Liao Z; In Wong K; He F; Singh S; Loomba R; Karin M; Witztum JL; Saltiel AR
    Science; 2020 Feb; 367(6478):652-660. PubMed ID: 32029622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTZ attenuates liver steatosis and fibrosis in the minipigs with type 2 diabetes by regulating the AMPK signaling pathway.
    Wang H; Huang M; Bei W; Yang Y; Song L; Zhang D; Zhan W; Zhang Y; Chen X; Wang W; Wang L; Guo J
    Biomed Pharmacother; 2021 Jun; 138():111532. PubMed ID: 34311531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct AMPK Activation Corrects NASH in Rodents Through Metabolic Effects and Direct Action on Inflammation and Fibrogenesis.
    Gluais-Dagorn P; Foretz M; Steinberg GR; Batchuluun B; Zawistowska-Deniziak A; Lambooij JM; Guigas B; Carling D; Monternier PA; Moller DE; Bolze S; Hallakou-Bozec S
    Hepatol Commun; 2022 Jan; 6(1):101-119. PubMed ID: 34494384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of nonalcoholic fatty liver disease: role of AMPK.
    Smith BK; Marcinko K; Desjardins EM; Lally JS; Ford RJ; Steinberg GR
    Am J Physiol Endocrinol Metab; 2016 Oct; 311(4):E730-E740. PubMed ID: 27577854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
    Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
    Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Research progress on AMPK activation in nonalcoholic fatty liver disease].
    Ye XY; Li TX; Huang ZW; Fu WW; Li Q
    Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1220-1223. PubMed ID: 38238958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Obesity-induced miR-802 directly targets AMPK and promotes nonalcoholic steatohepatitis in mice.
    Sun H; Seok S; Jung H; Kemper B; Kemper JK
    Mol Metab; 2022 Dec; 66():101603. PubMed ID: 36126896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA regulation of AMPK in nonalcoholic fatty liver disease.
    Sun H; Kemper JK
    Exp Mol Med; 2023 Sep; 55(9):1974-1981. PubMed ID: 37653034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of AMPK by triptolide alleviates nonalcoholic fatty liver disease by improving hepatic lipid metabolism, inflammation and fibrosis.
    Huang R; Guo F; Li Y; Liang Y; Li G; Fu P; Ma L
    Phytomedicine; 2021 Nov; 92():153739. PubMed ID: 34592488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gossypetin Prevents the Progression of Nonalcoholic Steatohepatitis by Regulating Oxidative Stress and AMP-Activated Protein Kinase.
    Oh E; Lee J; Cho S; Kim SW; Won K; Shin WS; Gwak SH; Ha J; Jeon SY; Park JH; Song IS; Thoudam T; Lee IK; Kim S; Choi SY; Kim KT
    Mol Pharmacol; 2023 Nov; 104(5):214-229. PubMed ID: 37595967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G protein-coupled estrogen receptor 1 ameliorates nonalcoholic steatohepatitis through targeting AMPK-dependent signaling.
    Li L; Yao Y; Wang Y; Cao J; Jiang Z; Yang Y; Wang H; Ma H
    J Biol Chem; 2024 Mar; 300(3):105661. PubMed ID: 38246352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase.
    Lee JH; Baek SY; Jang EJ; Ku SK; Kim KM; Ki SH; Kim CE; Park KI; Kim SC; Kim YW
    Chem Biol Interact; 2018 Jun; 289():68-74. PubMed ID: 29702089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A non-mitogenic FGF4 analog alleviates non-alcoholic steatohepatitis through an AMPK-dependent pathway.
    Wang L; Dong W; Gao H; Chen C; Liang S; Ye X; Liu Y; Hou Y; Fan L; Pan T; Wang Z; Chen Y; Luo Y; Song L
    Biochim Biophys Acta Mol Basis Dis; 2022 Dec; 1868(12):166560. PubMed ID: 36167161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of AMPKα2 in the HFD-induced nonalcoholic steatohepatitis.
    Zhang X; Liu S; Zhang C; Zhang S; Yue Y; Zhang Y; Chen L; Yao Z; Niu W
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165854. PubMed ID: 32502647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ménage à trois of autophagy, lipid droplets and liver disease.
    Filali-Mouncef Y; Hunter C; Roccio F; Zagkou S; Dupont N; Primard C; Proikas-Cezanne T; Reggiori F
    Autophagy; 2022 Jan; 18(1):50-72. PubMed ID: 33794741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.